Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Mar 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the best way to prevent blood clots in patients who have undergone a specific heart surgery known as coronary artery bypass grafting (CABG) combined with coronary endarterectomy (CE). This type of surgery is often necessary for patients with widespread coronary artery disease. The researchers want to see if adding a medication called warfarin to standard treatment with two types of antiplatelet drugs can help improve outcomes and reduce the risk of complications after surgery.

To participate in this study, you would need to be an adult aged 65 or older who is scheduled to have this combined surgery and does not have any conditions that would make the use of these medications risky. You should also be able to swallow tablets after the surgery. If you join the trial, you will be monitored closely to see how well the different treatments work. This study is currently looking for participants, and it’s a chance to help improve heart surgery care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
• • No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
• • Must be able to swallow tablets after the surgery.
• Exclusion Criteria:
• • 1. Patients with high bleeding risk (HAS-BLED ≥ 3);
• • 2. Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;
• • 3. Emergency surgery;
• • 4. Serum creatinine \>130μmol/L, or significant liver dysfunction (elevated ALT and/or AST);
• • 5. History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding;
• • 6. History of hemorrhagic stroke, or platelet dysfunction;
• • 7. Allergic or with contraindication to any of aspirin, clopidogrel or warfarin;
• • 8. Participated in other clinical trial for drug or device within 30 days;
• • 9. Pregnant or planning to be pregnant.